Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions

Bérengère Vire, Stéphane de Walque, Audrey Restouin et al. · 2009

Read Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions by Bérengère Vire, Stéphane de Walque, Audrey Restouin et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007085.txt.

Description

Bérengère Vire, Stéphane de Walque, Audrey Restouin, and colleagues tested a leukemia drug in PLOS ONE in 2009. Histone deacetylase inhibitors had shown promise against blood cancers in trials. One such drug, MS-275, kills leukemic blasts by triggering apoptosis. The killing was thought to run through death receptor pathways.

The team linked MS-275's activity to an immune pair, 4-1BBL and its receptor 4-1BB. That pair usually helps coordinate immune cells. If a cancer drug also wakes immune signaling, its benefits may be double. The finding suggests combining such drugs with immune therapies for leukemia.

Catalog record

CREATORBérengère Vire, Stéphane de Walque, Audrey Restouin et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007085

Browse the full library · About the Tower of Babel